Reduced platelet 5-HT content is associated with rest tremor in Parkinson's disease.

[1]  M. Tijssen,et al.  Dopaminergic and serotonergic alterations in plasma in three groups of dystonia patients. , 2021, Parkinsonism & related disorders.

[2]  Xiong Zhang,et al.  Prevalence of Alzheimer's Disease and Parkinson's Disease in China: An Updated Systematical Analysis , 2020, Frontiers in Aging Neuroscience.

[3]  Xiong Zhang,et al.  Association Analyses of Autonomic Dysfunction and Sympathetic Skin Response in Motor Subtypes of Parkinson's Disease , 2020, Frontiers in Neurology.

[4]  M. T. Pellecchia,et al.  Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study , 2019, The Lancet Neurology.

[5]  Xiong Zhang,et al.  SLC6A4 Repeat and Single-Nucleotide Polymorphisms Are Associated With Depression and Rest Tremor in Parkinson's Disease: An Exploratory Study , 2019, Front. Neurol..

[6]  W. Au,et al.  Non‐motor symptoms in early Parkinson's disease with different motor subtypes and their associations with quality of life , 2018, European journal of neurology.

[7]  X. Hong,et al.  Platelet serotonin and serotonin transporter as peripheral surrogates in depression and anxiety patients , 2018, European journal of pharmacology.

[8]  Günther Deuschl,et al.  Progression of tremor in early stages of Parkinson’s disease: a clinical and neuroimaging study , 2018, Brain : a journal of neurology.

[9]  J. Seibyl,et al.  Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease. , 2015, Brain : a journal of neurology.

[10]  G. Deuschl,et al.  MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[11]  James B. Adams,et al.  Correlation of serotonin levels in CSF, platelets, plasma, and urine. , 2012, Biochimica et biophysica acta.

[12]  R. Hays,et al.  Medication Responsiveness of Motor Symptoms in a Population-Based Study of Parkinson Disease , 2011, Parkinson's disease.

[13]  U. Bonuccelli,et al.  Differences in nigro‐striatal impairment in clinical variants of early Parkinson’s disease: evidence from a FP‐CIT SPECT study , 2010, European journal of neurology.

[14]  Thomas Gasser,et al.  Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria , 2009, The Lancet Neurology.

[15]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[16]  D. Brooks,et al.  Tremor in Parkinson’s disease and serotonergic dysfunction , 2003, Neurology.

[17]  S. Fahn,et al.  Mirtazapine in Parkinsonian tremor. , 2002, Parkinsonism & related disorders.

[18]  F. Crespi,et al.  Forced swimming test and fluoxetine treatment: in vivo evidence that peripheral 5-HT in rat platelet-rich plasma mirrors cerebral extracellular 5-HT levels, whilst 5-HT in isolated platelets mirrors neuronal 5-HT changes , 2002, Experimental Brain Research.

[19]  J. C. Stoof,et al.  Rigidity decreases resting tremor intensity in Parkinson's disease: A [123I]β‐CIT SPECT study in early, nonmedicated patients , 2001, Movement disorders : official journal of the Movement Disorder Society.

[20]  D J Wyper,et al.  Correlation of Parkinson's disease severity and duration with 123I‐FP‐CIT SPECT striatal uptake , 2000, Movement disorders : official journal of the Movement Disorder Society.

[21]  J. Jankovic,et al.  Variable expression of Parkinson's disease , 1990, Neurology.

[22]  S. Stahl.  The human platelet. A diagnostic and research tool for the study of biogenic amines in psychiatric and neurologic disorders. , 1977, Archives of general psychiatry.

[23]  L. Cote,et al.  Serotonin content of platelet enriched plasma in Parkinson patients prior and during treatment with L-3,4-dihydroxyphenylalanine (L-DOPA). , 1972, Biochemical medicine.